Benitec Biopharma Inc
NASDAQ:BNTC 3:59:44 PM EDT
| Market Cap (Intraday) | 20.43M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $4.38 |
| 50-Day MA | $4.58 |
| 200-Day MA | $4.03 |
Benitec Biopharma Inc Stock, NASDAQ:BNTC
3940 Trust Way, Hayward, California 94545
United States of America
Phone: +1.510.780.0819
Number of Employees: 14
Description
Benitec Biopharma, Inc. is a development-stage biotechnology company, which focuses on the advancement of novel genetic medicines. The firms proprietary platforms includes DNA-directed RNA interference, or ddRNAi, combines RNA interference, or RNAi, with gene therapy to create medicines that facilitates sustained silencing of disease-causing genes following a single administration. It is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy, and Chronic Hepatitis B. The company was founded on April 13, 2020 and is headquartered in Hayward, CA.